斯达外科手术 STAA 深 沪
等待开盘 06-03 09:30:00 美东时间
28.52
-1.030
-3.49%
华盛通- 最 高35.87
- 今 开29.55
- 成交量 51.62万股
- 最 低 26.38
- 昨 收 29.55
- 总市值 136.36万
- 52周最高 35.87
- 市盈率 静 57.57
- 换手率 1079.58%
- 52周最低 15.585
- 委 比 88.14%
- 总股本 4.78万
- 历史最高 163.08
- 量 比 0.50
- 振 幅 32.12%
- 历史最低 1.10
- 每 手 1
- 风险率 4.56%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多LENSAR Stock Plunges—Alcon Scraps Merger After Prolonged Regulatory Review
Alcon cancels $356 million LENSAR merger due to regulatory delays and FTC opposition, adding pressure on shares.
03-17 21:04
Earnings Breakdown: Staar Surgical Q4
The earnings results for Staar Surgical (NASDAQ:STAA) for Q4 were made public o...
03-04 05:20
FDA Expands Approval For Staar Surgical's Popular Implantable Lens
FDA expands Staar Surgical's EVO ICL approval for ages 21-60, offering a safer, non-LASIK alternative to millions.
02-18 18:18
STAAR Surgical Announces FDA Approves Expanded Age Indication For EVO/EVO+ Visian Implantable Collamer Lenses
STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that the U.S. Food and Drug
02-18 05:04
STAAR Surgical Appoints Warren Foust And Deborah Andrews As Interim Co-CEOs, Effective Immediately
STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction,
02-02 20:17
Alcon Targets Faster Growth In 2026 With New Cataract Surgery Systems
William Blair initiates Alcon with a Market Perform rating, citing strong pipeline, UNITY platform launches, and rising consumables growth, while noting the stock already trades at a premium.
01-31 02:00
STAAR Surgical Stock Falls After Largest Shareholder Broadwood Gains Board Influence
STAAR Surgical shares fell Thursday as new directors joined the board, key leaders exited, and Broadwood Partners pushed for changes following the failed Alcon merger.
01-16 02:06
STAAR Surgical To Terminate Alcon Merger After Failing To Secure Stockholder Approval
STAAR Intends to Terminate Alcon Merger AgreementSTAAR Surgical Company (NASDAQ:STAA) ("STAAR"), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision
01-06 21:48
Broadwood Slams STAAR–Alcon Deal as Flawed and Unfair to Shareholders
Broadwood Partners, L.P. and its affiliates (collectively, "Broadwood," "we," "us" or "our") today reacted to the proxy statement supplement filed by STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA) with
2025-12-11 20:12
Major Shareholder Rejects STAAR Surgical's Sale to Alcon Despite Higher $30.75 Offer
Yunqi Capital Limited (together with its affiliates and the funds it advises, "Yunqi Capital"), an investment management firm and 5.1% shareholder of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA), today
2025-12-10 20:10
